4//SEC Filing
Holm-Jorgensen Rasmus 4
Accession 0001140361-23-030544
CIK 0001781174other
Filed
Jun 19, 8:00 PM ET
Accepted
Jun 20, 5:21 PM ET
Size
17.0 KB
Accession
0001140361-23-030544
Insider Transaction Report
Form 4
Holm-Jorgensen Rasmus
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-06-16−9,500→ 183,119 totalExercise: $3.63Exp: 2032-06-28→ Common Stock (9,500 underlying) - Exercise/Conversion
Common Stock
2023-06-16$3.63/sh+9,500$34,485→ 29,530 total
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vested on April 20, 2023, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
Documents
Issuer
Acrivon Therapeutics, Inc.
CIK 0001781174
Entity typeother
Related Parties
1- filerCIK 0001950496
Filing Metadata
- Form type
- 4
- Filed
- Jun 19, 8:00 PM ET
- Accepted
- Jun 20, 5:21 PM ET
- Size
- 17.0 KB